目的 研究右美托咪定对胶质瘤细胞U251体外恶性生长和侵袭的影响和机制。方法 以胶质瘤细胞U251作为体外研究对象,右美托咪定处理U251细胞,四甲基偶氮唑蓝(MTT)方法检测细胞增殖情况,Transwell小室测定细胞侵袭和迁移变化,Western blot检测细胞中基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)和p-AKT蛋白表达。用AKT信号激活剂和右美托咪定联合处理胶质瘤细胞,检测细胞增殖、侵袭和迁移能力。结果 右美托咪定可降低胶质瘤细胞增殖、侵袭及迁移能力,抑制MMP-2、MMP-9、p-AKT蛋白表达;AKT信号激活剂处理可逆转右美托咪定对胶质瘤细胞增殖、侵袭和迁移能力的影响。结论 右美托咪定通过抑制AKT信号通路阻碍胶质瘤细胞U251体外恶性生长和侵袭。
Abstract
OBJECTIVE To study the effect and mechanism of dexmedetomidine on the malignant growth and invasion of glioma cell line U251 in vitro. METHODS Using glioma cell U251 as an in vitro study, treated with dexmedetomidine, MTT assay was used to measure the cell proliferation, Transwell chambers was used to measure the changes in cell invasion and migration, and the expressions of MMP-2, MMP-9 and p-AKT protein in cells were detected by Western blot. Glioma cells were treated with AKT signaling activator and dexmedetomidine, and cell proliferation, invasion and migration were observed. RESULTS Dexmedetomidine can reduce the proliferation, invasion and migration of glioma cells and inhibit the expression of MMP-2, MMP-9 and p-AKT proteins. AKT signaling activator treatment reversed the effect of dexmedetomidine on the proliferation, invasion and migration of glioma cells. CONCLUSION Dexmedetomidine blocks malignant growth and invasion of glioma cell U251 in vitro by inhibiting AKT signaling.
关键词
右美托咪定 /
AKT信号 /
胶质瘤 /
侵袭
{{custom_keyword}} /
Key words
dexmedetomidine /
AKT signal /
glioma /
invasion
{{custom_keyword}} /
中图分类号：
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LOUIS D N, GIANNINI C, CAPPER D, et al. cIMPACT-NOW update 2:diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol, 2018, 135(4):639-642.
[2] LAU D, HERVEY-JUMPER S L, HAN S J, et al. Intraoperative perception and estimates on extent of resection during awake glioma surgery:overcoming the learning curve. J Neurosurg, 2018, 128(5):1410-1418.
[3] FREEMAN J, BUGGY D J. Modelling the effects of perioperative interventions on cancer outcome:lessons from dexmedetomidine. Br J Anaesth, 2018, 120(1):15-17.
[4] FAN Z B. Effect of intraoperative dexmedetomidine on post-craniotomy pain. Pract Pharm Clin Remed(实用药物与临床), 2016, 19(2):193-196.
[5] LIAN H M, JIANG L H. Effects of dexmedetomidine on the biological behavior of ovarian cancer cells. Pract Pharm Clin Remed(实用药物与临床), 2018, 21(4):369-373.
[6] ZENG L, YANG L Y, MO L P, et al. Effects of dexmedetomidine on the proliferation, migration and apoptosis of human breast carcinoma cell line MCF-7. J Clin Anesthesiol(临床麻醉学杂志), 2014, 30(1):74-76.
[7] WANG Y Q, TANG Y F, YANG M K, et al. Dexmedetomidine alleviates cerebral ischemia-reperfusion injury in rats via inhibition of hypoxia-inducible factor-1α. J Cell Biochem, 2019, 120(5):7834-7844.
[8] JAYAPRAKASH A, OSMANI S G, SURESH Y A, et al. Effect of intravenous dexmedetomidine on spinal anaesthesia with hyperbaric bupivacaine in lower limb orthopedic surgeries-a randomized controlled study. Indian J Public Health Res Develop, 2018, 9(12):311-316.
[9] LAAKSONEN L, KALLIOINEN M, LNGSJ J, et al. Comparative effects of dexmedetomidine, propofol, sevoflurane, and S-ketamine on regional cerebral glucose metabolism in humans:a positron emission tomography study. Br J Anaesth, 2018, 121(1):281-290.
WANG S B, WANG X T, XUE R L. Effects of dexmedetomidine on cell growth and metastasis of human cervical cancer cell Hela. J Region Anatomy Operat Surg(局解手术学杂志), 2018, 27(12):12-16.
CAGGIA S, CHUNDURI H B, MILLENA A C, et al. Novel role of Giα2 in cell migration: downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells. J Cell Physiol, 2019, 234(1):802-815.
SONG W, MEI J Z, ZHANG M. Long noncoding RNA PlncRNA-1 promotes colorectal cancer cell progression by regulating the PI3K/Akt signaling pathway. Oncol Res Featur Preclin Clin Cancer Therap, 2018, 26(2):261-268.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(4472 KB)
